Ambrx Biopharma Inc.

Ambrx Biopharma Inc.verified

AMAM

Price:

$28

Market Cap:

$1.77B

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of pro...[Read more]

Industry

Biotechnology

IPO Date

2023-08-14

Stock Exchange

NYSE

Ticker

AMAM

The PE Ratio as of July 2024 (TTM) for Ambrx Biopharma Inc. (AMAM) is 66.67

According to Ambrx Biopharma Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 66.67. This represents a change of -1022.73% compared to the average of -7.22 of the last 4 quarters.

Ambrx Biopharma Inc. (AMAM) Historical PE Ratio (quarterly & annually)

How has AMAM PE Ratio performed in the past?

The mean historical PE Ratio of Ambrx Biopharma Inc. over the last ten years is -17.15. The current 66.67 PE Ratio has changed -38963.66% with respect to the historical average. Over the past ten years (40 quarters), AMAM's PE Ratio was at its highest in in the March 2021 quarter at -0.75. The PE Ratio was at its lowest in in the March 2020 quarter at -30.50.

Quarterly (TTM)
Annual

Average

-17.15

Median

-15.74

Minimum

-36.00

Maximum

-1.12

Ambrx Biopharma Inc. (AMAM) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Ambrx Biopharma Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 25.08%

Maximum Annual PE Ratio = -1.12

Minimum Annual Increase = -92.49%

Minimum Annual PE Ratio = -36.00

Quarterly (TTM)
Annual
YearPE RatioChange
2022-1.12-58.46%
2021-2.70-92.49%
2020-36.0025.08%

Ambrx Biopharma Inc. (AMAM) Average PE Ratio

How has AMAM PE Ratio performed in the past?

The current PE Ratio of Ambrx Biopharma Inc. (AMAM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-13.28

5-year avg

-17.15

10-year avg

-17.15

Ambrx Biopharma Inc. (AMAM) PE Ratio vs. Peers

How is AMAM’s PE Ratio compared to its peers?

Ambrx Biopharma Inc.’s PE Ratio is greater than Immix Biopharma, Inc. (-2.68), greater than CNS Pharmaceuticals, Inc. (-0.52), greater than eFFECTOR Therapeutics, Inc. (-0.01), greater than Navidea Biopharmaceuticals, Inc. (0.03), greater than Sonnet BioTherapeutics Holdings, Inc. (-0.47), greater than CohBar, Inc. (-0.11), greater than Enveric Biosciences, Inc. (-0.12), greater than Elevation Oncology, Inc. (-3.18), greater than Hepion Pharmaceuticals, Inc. (-0.13), greater than Zura Bio Limited (-3.18), greater than Ocean Biomedical, Inc. (-0.19), greater than AVROBIO, Inc. (2.07), greater than Day One Biopharmaceuticals, Inc. (-6.21), greater than Acumen Pharmaceuticals, Inc. (-3.07), greater than X4 Pharmaceuticals, Inc. (-1.18), greater than Inozyme Pharma, Inc. (-4.27), greater than VectivBio Holding AG (-7.94),

Build a custom stock screener for Ambrx Biopharma Inc. (AMAM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ambrx Biopharma Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Ambrx Biopharma Inc. (AMAM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Ambrx Biopharma Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Ambrx Biopharma Inc.'s PE Ratio?

How is the PE Ratio calculated for Ambrx Biopharma Inc. (AMAM)?

What is the highest PE Ratio for Ambrx Biopharma Inc. (AMAM)?

What is the 3-year average PE Ratio for Ambrx Biopharma Inc. (AMAM)?

What is the 5-year average PE Ratio for Ambrx Biopharma Inc. (AMAM)?

How does the current PE Ratio for Ambrx Biopharma Inc. (AMAM) compare to its historical average?